Amy E. Foxx-Orenstein, D.O.

This study will evaluate obesity as a comorbidity in a population of patients with irritable bowel syndrome (IBS), and assess this cohort for vitamin D-deficiency. It will also determine whether alterations in the fecal microbiome and metaproteome, associated with vitamin D deficiency or other factors, underpin obesity-IBS comorbidity.

Microbiota from fecal samples from IBS-D patients, in combination with vitamin D supplementation added to our 3-D immunocompetent intestinal models will establish a high fidelity disease model to achieve our long-term goal to understand the relationship between gut microbiome, vitamin D levels, host gene expression and IBS-D symptoms that could ultimately be used as a testing platform for treatment and prevention.

The purpose of this observational study is to evaluate the safety and effectiveness of the Solesta Injectable Bulking Agent in the treatment of fecal incontinence through 3 years in a real world setting.

Supporting the pelvic floor can reduce symptoms of constipation in patients with refractory constipation due to pelvic floor laxity and excessive perineal descent by means of a modified toilet seat, known as "the Bottom's Up".

The purpose of this project is to complete a chart review/ secondary data analysis during the first 6-month program period utilizing data from the 4291 PARTENHEIMER Obesity Registry and interval participant data from the Mayo360 Personalized Support System (Mayo360PSP) questionnaire to examine motivation and behavioral changes in program participants.

The purpose of this study is to establish a registry database of patients that will be utilized for future research studies related to obesity, health, and weight management strategies.